LabCorp Launches Over 100 Tests, Targets 2–3x Faster Growth in Key Areas
At the 44th Annual J.P. Morgan Healthcare Conference, LabCorp CEO Adam Schechter revealed the company launched over 100 diagnostic tests in 2025 across oncology, women’s health, autoimmune and neurology—segments expected to grow 2–3x faster than the broader diagnostic market. He cited solid core fundamentals last year driven by successful M&A integration and enhanced organic growth.
1. LabCorp Highlights Strategic Growth in Core Therapeutic Areas
At the 44th Annual J.P. Morgan Healthcare Conference, LabCorp Holdings Inc. President and CEO Adam Schechter underscored the company’s strong 2025 performance, driven by both M&A integration and improved organic growth. LabCorp launched over 100 new diagnostic tests last year, with a concentrated effort in four core therapeutic areas—oncology, women’s health, autoimmune and neurology—which Schechter noted are projected to expand two to three times faster than the broader diagnostics market. He emphasized that these launches, coupled with disciplined integration of recent acquisitions, have bolstered LabCorp’s ability to deliver higher-margin services and strengthen its pipeline for 2026.